Fig. 8

CISD inhibitors induce mitophagy and rescue rescues Pink1 and parkin mutant phenotypes. A Confocal microscopy analysis of WT ARPE-19 cells expressing mito-QC to visualise mitolysosomes (shown separately) treated with 100 µM rosiglitazone (Rosi), NL1 or vehicle. B Quantification of the number of mitolysosomes per cell of conditions shown in A. Data points indicate replicate experiments. Statistical analysis: RM one-way ANOVA with Geisser-Greenhouse correction; *P < 0.05; ****P < 0.0001. C Analysis of Climbing, (D) thoracic indentations and drooped-wing phenotype, and (E) mitochondrial morphology in flight muscle of Pink1 and parkin mutants alongside WT control flies, treated with 1 mM rosiglitazone (Rosi) or vehicle. Statistical analysis: Chi-squared test. ***P < 0.001; ****P < 0.0001. Scale bars = 10 μm. F Immunoblot analysis of protein lysates from whole flies upon treatment with 1 mM rosiglitazone (Rosi) or vehicle. Samples were homogenised under reducing conditions and blots were probed for Cisd (CISD2, Proteintech, 13318-1-AP) and Tubulin